Skip to content
Screener

Alumis Inc. ALMS Common Stock

Common Stock at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$292M0.0%
Amgen logo
AmgenAMGN
2.8B0.0%
Immunome logo
ImmunomeIMNM
$11K+22.2%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
545M0.0%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
200M0.0%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$6K0.0%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.52B+693%
Enterprise value$3.49B+955%
P/S418.8×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The source filing: Alumis Inc.’s 10-Q, filed August 13, 2024.

Filed
Aug 13, 2024
Fiscal quarter
Q2 FY2024
Calendar quarter
Q2 2024
Accession
0001558370-24-012081
(in thousands, except share and per share amounts)June 30, 2024December 31, 2023
Commitments and contingencies (Note 7)
Redeemable convertible preferred stock, $0.0001 par value; 202,643,727 and 89,016,578 shares authorized as of June 30, 2024 and December 31, 2023, respectively; 168,489,871 and 85,960,088 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively; aggregate liquidation preference of $629,540 and $370,540 as of June 30, 2024 and December 31, 2023, respectively639,237375,370
Stockholders’ deficit:
Common stock, $0.0001 par value; 225,000,000 and 125,000,000 Class A shares authorized as of June 30, 2024 and December 31, 2023, respectively; 2,741,498 and 2,675,979 Class A shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively; 168,489,897 and 85,960,088 Class B shares authorized as of June 30, 2024 and December 31, 2023, respectively; no Class B shares issued and outstanding as of June 30, 2024 and December 31, 202311
Additional paid-in capital31,92025,055
Accumulated other comprehensive (loss) income(1)2
Accumulated deficit(470,675)(364,318)
Total stockholders’ deficit(438,755)(339,260)

Item 1. Financial Statements (Unaudited)

FAQ

What is Alumis Inc.'s common stock?
Alumis Inc. (ALMS) reported common stock of $1K in Q2 2024.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about Alumis Inc.'s common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude